17D yellow fever vaccine elicits comparable long-term immune responses in healthy individuals and immune-compromised patients

Journal of Infection

Volumn 72, Issue 6, 2016, Pages 713-722

  Wieten, R W ^a   Goorhuis, A ^a   Jonker, E F F ^b   de Bree, G J ^a   de Visser, A W ^b   van Genderen, P J J ^c   Remmerswaal, E B M ^d   ten Berge, I J M ^a   Visser, L G ^b   Grobusch, M P ^a   van Leeuwen, E M M ^d  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Harbour Hospital   (Netherlands)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

17D yellow fever; Immune compromised; Vaccination

Indexed keywords

CYTOKINE; NEUTRALIZING ANTIBODY; TETRAMER; VIRUS ANTIBODY; YELLOW FEVER VACCINE;

ADULT; AGED; ANTIBODY TITER; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HUMAN; HUMAN CELL; IMMUNOCOMPROMISED PATIENT; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; INNATE IMMUNITY; LYMPHOCYTE PROLIFERATION; MALE; MEMORY CELL; MIDDLE AGED; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; SERODIAGNOSIS; VACCINATION; YELLOW FEVER; YELLOW FEVER VIRUS; BIOSYNTHESIS; BLOOD; IMMUNOLOGY; NORMAL HUMAN; TIME FACTOR; YOUNG ADULT;

ADULT; AGED; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; FEMALE; HEALTHY VOLUNTEERS; HUMANS; IMMUNOCOMPROMISED HOST; MALE; MIDDLE AGED; NEUTRALIZATION TESTS; TIME FACTORS; VACCINATION; YELLOW FEVER VACCINE; YELLOW FEVER VIRUS; YOUNG ADULT;

EID: 84962727052     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2016.02.017     Document Type: Article

References (36)

1. Teichmann D., Grobusch M.P., Wesselmann H., Temmesfeld-Wollbrück B., Breuer T., Dietel M., et al. A haemorrhagic fever from the Côte d'Ivoire. Lancet 1999, 354:1608.
2. Monath T.P., Cetron M.S., Teuwen D.E. Yellow fever vaccine. Vaccines 2008, 959-1056. Saunders Elsevier, Philadelphia. 5th ed. S.A. Plotkin, W.A. Orenstein, P.A. Offit (Eds.).
3. Gotuzzo E., Yactayo S., Cordova E. Review article: efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years. Am J Trop Med Hyg 2013, 89:434-444.
4. Veit O., Niedrig M., Chapuis-Taillard C., Cavassini M., Mossdorf E. Immunogenicity and safety of yellow fever vaccination of 102 HIV infected patients. Clin Infect Dis 2009, 48:659-666.
5. Pacanowski J., Lacombe K., Campa P., Dabrowska M., Poveda J.D., Meynard J.L., et al. Plasma HIV-RNA is the key determinant of long-term antibody persistence after yellow fever immunization in a cohort of 364 HIV infected patients. J Acquir Immune Defic Syndr 2012, 59:360-366.
6. Sidibe M., Yactayo S., Kalle A., Sall A.A., Sow S., Ndoutabe M., et al. Immunogenicity and safety of yellow fever vaccine among 115 HIV-infected patients after a preventive immunisation campaign in Mali. Trans R Soc Trop Med Hyg 2012, 106:437-444.
7. Akondy R.S., Monson N.D., Miller J.D., Edupuganti S., Teuwen D., Wu H., et al. The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T-cell response. J Immunol 2009, 183:7919-7930.
8. Dutch national guidelines on travellers' medicine 2008, LCR National Coordination Centre for Travelers' Health, Landelijk Coordinatiecentrum Reizigersadvisering, Amsterdam.
9. CDC Yellow book [accessed September 05.09.15]. http://wwwnc.cdc.gov/travel/yellowbook/2014/chapter-8-advising-travelers-with-specific-needs/immune-compromised-travelers.
10. Wieten R.W., Jonker E.F., Pieren D.K., Hodiamont C.J., van Thiel P.P., van Gorp E.C., et al. Comparison of the PRNT and an immune fluorescence assay in yellow fever vaccinees receiving immunosuppressive medication. Vaccine 2016, [Epub ahead of print]. 10.1016/j.vaccine.2016.01.037.
11. Requirements for yellow fever vaccine. WHO Tech Rep Ser 1976, 594:23-49. World Health Organization.
12. Cohen B.J., Parry R.P., Doblas D., Samuel D., Warrener L., Andrews N., et al. Measles immunity testing: comparison of two measles IgG ELISAs with plaque reduction neutralisation assay. J Virol Methods 2006, 131:209-212.
13. Blom K., Braun M., Ivarsson M.A., Gonzalez V.D., Falconer K., Moll M., et al. Temporal dynamics of the primary human T-cell response to yellow fever virus 17D as it matures from an effector to a memory type response. J Immunol 2013, 190:2150-2158.
14. Guy B., Nougarede N., Begue S., Sanchez V., Souag N., Carre M., et al. Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects. Vaccine 2008, 26:5712-5721.
15. Co M.D., Kilpatrick E.D., Rothman A.L. Dynamics of the CD8 T-cell response following yellow fever virus 17D immunization. Immunology 2009, 128:e718-e727.
16. Sallusto F., Lenig D., Förster R., Lipp M., Lanzavecchia A. Pillars article: two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999, 401:708-712. J Immunol 2014; 192: 840-844.
17. Intlekofer A.M., Takemoto N., Wherry E.J., Longworth S.A., Northrup J.T., Palanivel V.R., et al. Effector and memory CD8+ T-cell fate coupled by T-bet and eomesodermin. Nat Immunol 2005, 6:1236-1244.
18. Pearce E.L., Mullen A.C., Martins G.A., Krawczyk C.M., Hutchins A.S., Zediak V.P., et al. Control of effector CD8+ T-cell function by the transcription factor Eomesodermin. Science 2003, 302:1041-1043.
19. Szabo S.J., Sullivan B.M., Stemmann C., Satoskar A.R., Sleckman B.P., Glimcher L.H. Distinct effects of T-bet in TH1 lineage commitment and IFN-gamma production in CD4 and CD8 T-cells. Science 2002, 295:338-342.
20. + memory T-cells. J Virol 2008, 82:10017-10031.
21. Appay V., Dunbar P.R., Callan M., Klenerman P., Gillespie G.M., Papagno L., et al. Memory CD8+ T-cells vary in differentiation phenotype in different persistent virus infections. Nat Med 2002, 8:379-385.
22. Bassi M.R., Kongsgaard M., Steffensen M.A., Fenger C., Rasmussen M., Skjødt K., et al. CD8+ T-cells complement antibodies in protecting against yellow fever virus. J Immunol 2015, 194:1141-1153.
23. Appay, van Lier, Sallusto, Roederer Phenotype and function of human T lymphocyte subsets: consensus and issues. Cytometry A 2008, 73:975-983.
24. Hamann D., Baars P.A., Rep M.H., Hooibrink B., Kerkhof-Garde S.R., Klein M.R., et al. Phenotypic and functional separation of memory and effector human CD8+ T-cells. J Exp Med 1997, 186:1407-1418.
25. van Aalderen M.C., Remmerswaal E.B., ten Berge I.J., van Lier R.A. Blood and beyond: properties of circulating and tissue-resident human virus-specific αβ CD8(+) T-cells. Eur J Immunol 2014, 44:934-944.
26. Gamadia L.E., Remmerswaal E.B., Weel J.F., Bemelman F., van Lier R.A., ten Berge I.J. Primary immune responses to human CMV: a critical role for IFN-gamma-producing CD4+ T-cells in protection against CMV disease. Blood 2003, 101:2686-2692.
27. Blom K., Braun M., Pakalniene J., Dailidyte L., Béziat V., Lampen M.H., et al. Specificity and dynamics of effector and memory CD8 T-cell responses in human tick-borne encephalitis virus infection. PLoS Pathog 2015, 11:e1004622.
28. Nabeshima S., Murata M., Kikuchi K., Ikematsu H., Kashiwagi S., Hayashi J. A reduction in the number of peripheral CD28+CD8+T-cells in the acute phase of influenza. Clin Exp Immunol 2002, 128:339-346.
29. de Bree G.J., van Leeuwen E.M., Out T.A., Jansen H.M., Jonkers R.E., van Lier R.A. Selective accumulation of differentiated CD8+ T-cells specific for respiratory viruses in the human lung. J Exp Med 2005, 202:1433-1442.
30. Schluns K.S., Kieper W.C., Jameson S.C., Lefrancois L. Interleukin-7 mediates the homeostasis of naive and memory CD8 T-cells in vivo. Nat Immunol 2000, 1:426-432.
31. Wrammert J., Miller J., Akondy R., Ahmed R. Human immune memory to yellow fever and smallpox vaccination. J Clin Immunol 2009, 29:151-157.
32. Flynn J.K., Gorry P.R. Stem memory T-cells (TSCM)- their role in cancer and HIB immunotherapies. Clin Transl Immunol 2014, 3:e20.
33. Gattinoni L., Lugli E., Ji Y., Pos Z., Paulos C.M., Quigley M.F., Almeida J.R., et al. A human memory T-cell subset with stem cell-like properties. Nat Med 2011, 17:1290-1297.
34. Lugli E., Dominguez M.H., Gattinoni L., Chattopadhyay P.K., Bolton D.L., Song K., et al. Superior T memory stem cell persistence supports long-lived T-cell memory. J Clin Invest 2013, 123:594-599.
35. Fuertes Marraco S.A., Soneson C., Cagnon L., Gannon P.O., Allard M., Abed Maillard S., et al. Long lasting stem cell-like memory CD8+ T-cells with a naïve like profile upon yellow fever vaccination. Sci Transl Med 2015, 7. 282ra48.
36. Darrah P.A., Patel D.T., De Luca P.M., Lindsay R.W., Davey D.F., Flynn B.J., et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 2007, 13:843-850.